Trump and WHO Leader

So Trump Was Right As WHO FINALLY Resume Hydrochloroquine Trial

The WHO has now resumed studies on hydrochlroquine as a possible cure for the treatment of Covid-19, this is coming after it erroneously followed a study which misled the top Organization. The study which influenced the decision of the World Health Organisation to initially suspend hydrochloroquine trial for treating COVID-19 patients has been retracted over inaccessible data.

WHO Logo

A study published by The Lancet, a medical journal, on May 22nd claimed chloroquine had no positive effect on the treatment of COVID-19 after carrying out experiments and trials on 96,032 sampled patients.

However, on May 25th, Tedros Ghebreyesus, the WHO director-general, announced a “temporary pause” in the WHO solidarity trial of the drug, also citing the study.

However, an investigation by UK Guardian showed that the data used by The Lancet, which was obtained from Surgisphere, a US-based company, was questionable and possibly inaccurate.

Subsequently, an independent audit of the validity and accuracy of the data was launched over “concerns that have been raised about the reliability of the database.”

In the retraction note published by the journal on Thursday, Mandeep Mehra, medical director of Brigham and Women’s Hospital Heart and Vascular Center, and one of the three co-authors who led the research, apologised profusely over the questionable publication.


The authors regrettably noted that an independent and private peer review of the study could not take place because such “would violate client agreements and confidentiality requirements.”

They said,

“Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements,” the statement read.

“As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process.

“We all entered this collaboration to contribute in good faith and at a time of great need during the Covid-19 pandemic.

“We deeply apologise to you, the editors, and the journal readership for any embarrassment or inconvenience that this may have caused.”

WHO has now announced resumption of hydrochloroquine trial after a review of the data.

This new development will now be a top point for US President Donald Trump who first recommended the use of the drug for treatment of Covid-19 but was heavily criticized by opponents and the World Health Organization. is headed by Jayamma Abanobi and it is one of the fastest growing News and Information outlet in Nigeria

Leave a Reply

Your email address will not be published.